Last reviewed · How we verify
Bilhvax vaccine (Sh28GST)
Bilhvax is a recombinant vaccine targeting schistosome antigens to induce immune responses against Schistosoma haematobium infection.
Bilhvax is a recombinant vaccine targeting schistosome antigens to induce immune responses against Schistosoma haematobium infection. Used for Schistosomiasis haematobium (urogenital schistosomiasis).
At a glance
| Generic name | Bilhvax vaccine (Sh28GST) |
|---|---|
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France |
| Drug class | Recombinant protein vaccine |
| Target | Sh28GST (Schistosoma haematobium 28 kDa glutathione S-transferase) |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | Phase 3 |
Mechanism of action
The vaccine uses the Sh28GST antigen, a glutathione S-transferase fusion protein derived from S. haematobium, to stimulate both cellular and humoral immunity against the parasite. This approach aims to reduce parasite burden and associated morbidity in infected individuals by enhancing the host's natural immune defenses against schistosomiasis.
Approved indications
- Schistosomiasis haematobium (urogenital schistosomiasis)
Common side effects
- Local injection site reactions
- Fever
- Myalgia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: